Iberdomide Accelerated Approval: CELMoD Platform Validated, But Confirmatory Trial Risk Looms Over BMS's Franchise Pivot

FDA Grants Accelerated Approval to BMS's Zenbexus for Multiple Myeloma

The FDA has granted accelerated approval to Bristol Myers Squibb's iberdomide, branded as Zenbexus, for the treatment of multiple myeloma. This approval is for use in combination with dexamethasone and Johnson & Johnson’s Darzalex in patients who have undergone at least one prior line of treatment. Zenbexus, the first approval from BMS's CELMoD platform, aims to bolster the company's position in the multiple myeloma market as sales of its existing drugs, Revlimid and Pomalyst, face significant erosion from generics, plummeting 49% and 71% year-on-year respectively in Q2. Despite these declines, BMS reported a 5% increase in total Q2 revenue to $12.97 billion and lifted its 2026 sales guidance to $49.5 billion. Zenbexus carries a boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism, and requires a late-stage confirmatory study for full approval.

• The accelerated approval of Zenbexus (iberdomide) by the FDA is a significant regulatory milestone for Bristol Myers Squibb. The drug is indicated for multiple myeloma patients who have received at least one prior line of therapy, to be used in a regimen with dexamethasone and Darzalex. This approval was supported by data from the Phase 3 EXCALIBER-RRMM study, which demonstrated a significantly higher rate of minimal residual disease (MRD)-negative complete response with the Zenbexus-based regimen compared to standard of care.
• Zenbexus is priced at $29,500 for a 28-day cycle and is projected to achieve over $1 billion in annual earnings by 2031, offering a crucial new revenue stream for BMS. This comes as the company grapples with substantial sales declines for its established multiple myeloma drugs, Revlimid and Pomalyst, which saw Q2 sales drop by 49% to $425 million and 71% to $204 million, respectively, due to generic competition. The new drug is central to BMS's strategy to regain market share in the indication.
• Zenbexus represents the inaugural approval for Bristol Myers Squibb’s innovative CELMoD platform, which leverages the body's natural protein degradation system to target and eliminate abnormal cancer-causing proteins. This approval validates the platform's potential, with another CELMoD candidate, mezigdomide, currently under FDA review for relapsed or refractory multiple myeloma, with a decision anticipated in May 2027, indicating a robust pipeline in this therapeutic area.

Addressing Unmet Needs in Relapsed Multiple Myeloma

Despite meaningful advances in multiple myeloma therapeutics, the disease remains incurable, with virtually all patients eventually relapsing or becoming refractory to available treatments. The challenges are multifactorial, spanning biological resistance mechanisms, toxicity profiles, and systemic access barriers that collectively constrain long-term outcomes.

• Drug resistance and clonal evolution: The primary obstacle to durable remission is the clonal evolution of myeloma cells under therapeutic pressure, compounded by bone marrow microenvironmental changes that confer progressive resistance and drive relapse.

• BCMA target antigen loss: Loss of BCMA expression following BCMA-directed therapy is an emerging and clinically significant resistance mechanism. Patients with prior therapy-mediated downregulation of plasma cell BCMA expression have uniformly failed to respond to subsequent anti-BCMA agents such as teclistamab; in at least one case, whole exome sequencing confirmed biallelic loss of TNFRSF17 following belantamab mafodotin exposure.

• CAR-T manufacturing delays: The 6–8 week production timeline for BCMA-directed CAR-T therapies — including ciltacabtagene autoleucel and idecabtagene vicleucel — creates a clinically precarious window during which up to 10% of patients experience disease progression or death, underscoring the critical need for effective bridging strategies.

• Severe and complex immunotherapy toxicities: Novel immunotherapies carry a distinct toxicity burden, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS), delayed neurotoxicity, cytopenias, and opportunistic infections. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) presents a particularly difficult diagnostic and therapeutic challenge.

• High-risk cytogenetic disease: Patients harboring high-risk cytogenetic abnormalities — including t(4;14), t(14;16), t(14;20), del(17p), and amp1q21 — continue to carry a poor long-term prognosis despite the expanded treatment landscape.

• Immunosuppressive bone marrow microenvironment: Relapsed/refractory myeloma cells actively remodel the bone marrow niche into an immunosuppressive milieu, characterized by upregulation of inflammatory cytokines, accumulation of PD1⁺ γδ T-cells, expansion of tumor-associated macrophages, and depletion of hematopoietic progenitors — all of which undermine the efficacy of immune-based therapies.

• Access and infrastructure limitations: The safe administration and monitoring of advanced immunotherapies requires specialized institutional infrastructure, creating meaningful disparities in access to care and restricting availability to select centers.

EXCALIBER-RRMM: Zenbexus's Efficacy and Safety Profile

Recent clinical trials in multiple myeloma have evaluated a range of combination regimens — from CD38-targeting antibodies with backbone triplet therapy to bispecific T-cell engagers — yielding important efficacy and safety data across transplant-eligible and transplant-ineligible settings. The studies below represent a cross-section of late-phase and consortium-level evidence shaping current and emerging treatment paradigms.

BMS's CELMoD Breakthrough: Navigating Opportunity and Risk

The recent accelerated approval of Zenbexus (iberdomide) marks a pivotal moment for Bristol Myers Squibb and the broader multiple myeloma (MM) treatment paradigm. As the first approved agent from BMS's innovative cereblon E3 ligase modulator (CELMoD) platform, Zenbexus arrives at a critical juncture, offering a much-needed new therapeutic avenue as the company's established immunomodulatory drugs (IMiDs) face significant generic competition. This strategic move not only diversifies BMS's oncology portfolio but also reinforces its commitment to addressing unmet needs in MM.

Iberdomide distinguishes itself as a next-generation CELMoD, demonstrating enhanced tumoricidal and immune-stimulatory effects compared to earlier IMiDs. Research indicates its ability to induce target substrate degradation even in patients refractory to prior IMiD therapies or those with low cereblon levels, alongside promoting a functional shift in T cells towards an activated phenotype. This mechanism of action underpins its meaningful clinical activity observed in heavily pretreated relapsed or refractory MM patients, including those with triple-class refractory disease, where treatment options are severely limited.

However, the path forward is not without considerations.

• The boxed warning for embryo-fetal toxicity and serious venous and arterial thromboembolism, a known class effect for IMiD-related compounds, necessitates robust risk evaluation and mitigation strategies. While Darzalex, a combination partner, has been associated with a lower risk of VTE, the overall thrombotic risk remains a critical factor for patient selection and management.

• Furthermore, the requirement for a late-stage confirmatory study introduces a degree of regulatory uncertainty, demanding continued investment and successful execution of ongoing trials to secure full approval.

• Clinicians will also need to manage common Grade 3/4 adverse events such as neutropenia, anemia, infection, and thrombocytopenia, which were frequently observed in clinical studies.

Despite these challenges, Zenbexus's entry into the market represents a significant step forward, offering a novel mechanism of action in combination with established agents for a challenging patient population. Its success will not only provide a new option for patients but also validate the potential of the CELMoD platform for future drug development in MM and potentially other hematologic malignancies.